Sarep­ta's Duchenne gene ther­a­py wins OK; FDA spurns NASH drug; Eli Lil­ly buys DICE for $2.4B; The new an­titrust land­scape; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

The End­points 11 is back. This year, John Car­roll will be team­ing up with Drew Arm­strong, Ryan Cross, An­drew Dunn and Kyle LaHu­cik to se­lect and pro­file the 2023 edi­tion of our an­nu­al re­port on some of the most promis­ing pri­vate biotechs out there. Nom­i­nate your fa­vorite biotech here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER